

# Journal of Advanced Pharmacy Research



## Section A: Natural Products & Metabolomics

### Common Applications of Black Cumin Seed (*Nigella sativa*) Oil in Folk Medicine

Rehab Hosni<sup>1</sup>, Hesham Hafez<sup>2,3\*</sup>, Hatem K. Amin<sup>2</sup>

<sup>1</sup> El Sisi Comprehensive Clinic, General Authority for Health Insurance-Giza, 12556, Giza, Egypt.

<sup>2</sup>Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Helwan University, 11795, Cairo, Egypt.

<sup>3</sup>Center of Scientific Excellence "Helwan Structural Biology Research, (HSBR)", Helwan University, 11795, Cairo, Egypt.

\*Corresponding author: Hesham Hafez, Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Helwan University, 11795, Cairo, Egypt. Tel.: +201094970173

E-mail address: [hesham.hafez@pharm.helwan.edu.eg](mailto:hesham.hafez@pharm.helwan.edu.eg)

Submitted on: 01-10-2022; Revised on: 01-11-2022; Accepted on: 04-11-2022

To cite this article: Hosni, R.; Hafez, H.; Amin, H. K. Common Applications of Black Cumin Seed (*Nigella sativa*) Oil in Folk Medicine. *J. Adv. Pharm. Res.* **2023**, 7 (1), 1-14. DOI: [10.21608/aprh.2022.166251.1196](https://doi.org/10.21608/aprh.2022.166251.1196)

#### ABSTRACT

**Objectives:** The seasonal plant *Nigella Sativa* (black cumin seed) has a broad range of medicinal effects. Black cumin seed oil (BCSO) has been found to have a range of advantageous effects as therapeutic or preventive therapy in varieties of diseases including hypertension, diabetes, obesity, and reproductive difficulties. **Methods:** the review collects potential medicinal applications and mechanisms for BCSO in the period between 1994 to 2022 from internationally accepted databases and scientific journals. **Results:** The oil also has been found to be a potent antioxidant and anti-inflammatory agent that renewed its interest as a low-risk dietary supplement. Additionally, it was shown that combinatorial therapy with other conventional chemotherapeutic medicines has a great synergistic effect allowing the reduction in the dosage of concurrently administered drugs while maintaining the optimal efficacy and minimizing or eliminating the global toxicity. **Conclusion:** The most prevalent substance of this volatile oil is thymoquinone (TQ), which is also the ingredient to which most of this herb's benefits are related. The current study shed light on the most valuable characteristics as well as traditional medicinal and biological principles of BCSO.

**Keywords:** BCSO, Thymoquinone, Antioxidant, Traditional, Dietary supplement.

#### INTRODUCTION

Cumin seeds are used as common food spices and aromatic plants. They are extensively spread in nations bordering the Mediterranean Sea, central Europe, and western Asia. The seeds are also employed in folk medicine in Saudi Arabia, India, China and the nations surrounding the Mediterranean Sea. In India, cumin (*Cuminum cyminum*), black cumin (*Nigella sativa*), and

bitter cumin (*C. nigrum*) are the three different types of cumin<sup>1</sup>. These previous types of mentioned cumin have common uses such as antioxidant activity through effect on lipid peroxidation and free radical scavenging mechanisms due to their higher phenolic content<sup>1</sup>. Black cumin seed oil (BCSO) is rich in highly active compounds such as fixed and volatile oils; fixed oil contains unsaturated fatty acids such as arachidonic, eicosadienoic, linoleic, linolenic, palmitic and myristic acid<sup>2</sup>, while the volatile oil consists of saturated fatty

acids as nigellone, thymoquinone (TQ), thymohydroquinone (THQ), dithymoquinone, thymol, carvacrol,  $\alpha$ - and  $\beta$ -pinene<sup>2</sup>.

BCSO has been used as a food and medicine for a very long time in India as a remedy for a number of illnesses and conditions including asthma<sup>3</sup>, cancer<sup>4,5</sup>, diabetes<sup>6,7</sup>, hypertension<sup>8,9</sup>, obesity<sup>10,11</sup>, inflammation<sup>12,13</sup> and hepatitis<sup>14,15</sup>. Thymoquinone (TQ) is the most common ingredient in the volatile oil of black cumin seed and is the primary factor in the herb's advantages. Many investigations have shown that crude black seed or its main active component TQ have varieties of biological activities include anti-cancer<sup>16-18</sup>, anti-oxytocic<sup>19</sup>, anti-tussive<sup>20</sup>, anti-inflammatory<sup>21,22</sup>, antipyretic<sup>23</sup>, analgesic<sup>21,24</sup> and anti-oxidant<sup>25,26</sup> outcomes. Additionally, the oil has wide spectrum of microbiological uses<sup>27</sup> such as antimicrobial activity<sup>28,29</sup>, anti-viral<sup>30,31</sup>, anti-parasitic<sup>32-34</sup> and anti-fungal<sup>35</sup> applications. BCSO has also been shown to alleviate the symptoms of different disorders including hypertension, dyslipidemia, diabetes<sup>18,36,37</sup>, asthma<sup>19</sup>, convulsions<sup>38,39</sup>, natural and chemical toxicities<sup>40,41</sup>. Moreover, the oil has protective effect against renal<sup>42</sup> and liver<sup>43</sup> complications. The current review demonstrates the possible medicinal uses of BCSO.

## MATERIALS AND METHODS

Authors collected all possible information about "phytochemical, pharmacological significance of BCSO" in the period from 1994 to 2022 that were published in all resources (journals, books,.....etc.) and found in different internationally recognized databases such as PubMed Central, Google scholars,.....etc. The collected data were selected, correlated to the main review objectives, and explained using potential documented mechanisms and different pathways.

## RESULTS AND DISCUSSION

### A. Safety profile of BCSO

After administering black cumin seed oil (5 mL/day) for 8 weeks to healthy individuals, no significant liver, renal, or gastrointestinal side effects were encountered<sup>44,45</sup>. A clinical trial has been performed on 39 significantly obese males and found that receiving three grams of black cumin seeds per day for three months had no discernible adverse effects<sup>46</sup>. Also, the treatment with black cumin seeds (2 gram per day for six weeks) showed no effect on serum parameters such as alanine aminotransferase (ALT) and creatinine levels in adult individuals<sup>46</sup>. Another clinical study found that consuming black cumin seed as supplement powder for 40 days had no effect on total leukocyte or platelet counts<sup>47</sup>.

### B. Medical application of BCSO

#### 1. Hypertension

The term "hypertension" means a 140 mmHg or higher increase in systolic blood pressure and/or 90 mmHg or higher increase in diastolic blood pressure<sup>48</sup>. Hypertension is a substantial risk element for heart disorders, stroke, and renal disease<sup>49</sup>. By the year 2025, about 15–25% of people, or around 1.5 billion people worldwide are expected to have hypertension<sup>50</sup>. About 29.5% of Egyptian individuals have hypertension<sup>51</sup>. The increase in the lipid peroxidation and oxidative stress have been shown to play key a role in the etiology of essential hypertension and the arterial damage associated with it<sup>52,53</sup>. *In-vivo* study was also conducted on 24 male rats which were treated with oral nicardipine once a day at a dose of 3 mg/kg and BCSO at a dose of 2.5 mg/kg respectively, for eight weeks, concurrently with L-NAME administration. In the L-NAME-treated rats, the results demonstrated that BCSO reduced the increase in systolic blood pressure<sup>54</sup>. BCSO also inhibits Rho-associated-kinase (ROCK), a critical mechanism in aortic relaxation, by limiting extracellular  $Ca^{+2}$  entrance<sup>55</sup>. Huseini *et al.* found that after administering black cumin seed oil (5 mL/day) as a crude dietary supplement to hypertensive patients for 2 months, their systolic and diastolic blood pressure decreased considerably when compared to the placebo and their baseline levels<sup>56</sup>. The positive impact was attributed to thymoquinone's antioxidant action against N- $\gamma$ -nitro-L-arginine methyl ester (L-NAME)-induced hypertension and kidney injury<sup>57</sup>. The blood pressure-lowering impact of BCSO and its cardiovascular depressant effects may be attributed to indirect and direct mechanisms mediated centrally in the brain stem<sup>58</sup>. Studies have found beneficial correlation between blood pressure, percent consumption of some components in BCSO as linoleic acid (57.71%) and oleic acid (24.46%)<sup>59-62</sup> that were detected and measured in the BCSO<sup>63</sup>. Total polyphenols as quercetin<sup>64</sup> and various flavonoids were also discovered and quantified in BCSO<sup>56</sup> that were responsible for blood pressure-lowering action due to their antioxidant properties as well as endothelium-dependent vasorelaxation<sup>65,66</sup>. Additionally, studies have shown that *N. Sativa's* antioxidant activity may be contributed to its major components of thymoquinone, dithymoquinone, and thymol<sup>57,67</sup>. Thymol is a singlet oxygen chelator, whereas thymoquinone (TQ) and dithymoquinone are free radical scavengers with Superoxide Dismutase (SOD)-like activity<sup>32,68,69</sup>. The free radical trapping activity of TQ is maintaining a harmony in the renin-angiotensin system and decreasing heart diseases via muscarinic and serotonin receptor dependent pathways<sup>70-72</sup>. Furthermore, the combinatorial effect of BCSO with sunflower oil in 2.5 mL twice daily for 8 weeks respectively in 26 treated patients with hypertension and 29 placebo showed a significant

reduction in diastolic blood pressure level, proving that using BCSO as a supplement to other oils had additional antihypertensive action<sup>73</sup>. The diuretic characteristics of *N. sativa* may be also responsible for its blood pressure-lowering effects<sup>72</sup>.

## 2. Obesity

Obesity means having a body mass index of 30 kg/m<sup>2</sup> or more<sup>74</sup>. Obesity has become so widespread cause for many infectious diseases<sup>75</sup> and other illness such as diabetes<sup>76,77</sup>, coronary heart diseases (CHD)<sup>78</sup>, certain types of cancer<sup>79</sup>, and sleep-breathing problems<sup>80,81</sup>. The worldwide prevalence was 14.0% in 2019<sup>82</sup> and about four million Egyptian individuals in 2020 suffered from obesity<sup>83</sup>. *In-vivo* studies revealed a decrease in appetite and food intake After utilizing *N. sativa* supplements as well as an increase in energy consumption, which could be the powerful anti-obesity mechanism of BCSO<sup>84,85</sup>. The soluble fiber content of BCSO may be a substantial factor to the sense of satiety and fullness<sup>84</sup>. After administering black cummin seed oil (2000 mg /day) to healthy obese women that underwent a 4-week washout period between two 8-week periods of supplementation, improvements in anthropometric and body structure measures were found and a notable reduction in hunger indicating that *N. sativa* supplements can help with obesity improvement<sup>86</sup>. Many studies suggested that *N. Sativa*'s hypolipidemic impact was due to its antioxidant capabilities, particularly TQ, which reduced lipid peroxidation and improved lipid metabolism<sup>87-89</sup>. After administering black cummin seed oil (3 g /day) to 50 obese women given a poor-calorie diet for 8 weeks, loss of weight in the black cummin group compared to the placebo group was observed<sup>90</sup>. Another clinical study conducted using 90 obese women to investigate the effect of BCSO combined with a poor-calorie diet on cardiometabolic risk variables in obese women<sup>84</sup>. Both the weight and waist circumference in the Black cummin seed oil group were considerably lower than placebo group with notable reduction in triglyceride and VLDL level. The major components of TQ, thymol, lipase, and unsaturated fatty acids, including arachidonic, linoleic, oleic, linolenic and eicosadienoic acids, unsaturated fatty acids, particularly polyunsaturated fatty acids (PUFA), have abilities to combat obesity and modify the link between the Lipoprotein lipase (LPL) rs320 gene and obesity<sup>91,92</sup>. After administering black cummin seed oil (1 g /day) to patients with hypercholesterolemia for 2 months, hypotriglyceridemic effect of BCSO on lipid profile was reported as it decreased the total cholesterol (TC), triglycerides (TG), LDL-C and increased HDL-C concentrations<sup>93,94</sup>. Unsaturated fatty acids modify the levels of TG and VLDL and have an impact on the production and catabolism of TG-rich lipoproteins.<sup>93,94</sup> Hypotriglyceridemic effect of BCSO improves insulin

resistance and fatty liver by reducing lipolysis and fat accumulation in adipocytes which reduce free fatty acid influx to the liver<sup>95</sup>.

## 3. Diabetes

Diabetes is an endocrine system disorder and one of the most common and quickly expanding diseases in the world characterized by unusually high blood glucose levels<sup>96</sup>. The risk of heart disease, dyslipidemia, infection, morbidity, and mortality can all rise as complications of metabolic disorders in diabetes<sup>97,98</sup>. World Health Organization (WHO) encourages researchers to explore the potential therapeutic characteristics and adverse effects of medicinal herbs in management of diabetes to avoid severe side effects of some chemical medications<sup>99</sup>. The International Diabetes Federation (IDF) estimates that there are currently more than 537 million diabetics worldwide<sup>100</sup> and about 15.2% in the adult individuals in Egypt had diabetes in early 2020<sup>101</sup>. It was confirmed by *In-vitro* investigation on the isolated pancreatic Islets of Langerhans that BCSO stimulated insulin secretion<sup>102</sup> and reduced the severity of degenerative and necrotic alterations<sup>103,104</sup>. A study demonstrated the hypoglycemic impact of BCSO in streptozotocin plus nicotinamide diabetic hamsters and data showed that it caused stimulatory influence on  $\beta$ -cell perform with a subsequent elevation in serum insulin concentration, and repairing activity of the pancreatic damage<sup>105</sup>. In type 2 diabetes animal model, findings showed that black seed oil has insulin tropic characteristics<sup>106,107</sup>. Kanter *et al.* also proved that BCSO has a pharmacological protective role against diabetes by decreasing oxidative stress and maintaining pancreatic  $\beta$ -cell integrity in diabetic animal model<sup>103,108,109</sup> with reduction in hepatic gluconeogenesis<sup>110</sup>. This was hypothesized because of TQ inhibits the expression of gluconeogenic enzymes and the generation of hepatic glucose by activating the adenosine monophosphate-activated protein kinase (AMPK) in muscles and liver, in addition to its capacity to reduce glucose absorption in the intestine<sup>111,112</sup>. Also, the administration of BCSO as 2 mL/kg to diabetic rats resulted in a significant increase in liver glycogen content due to increased pancreatic insulin production, which stimulates the glycogen synthase enzyme and lowers circulating glucose levels<sup>113</sup>. These findings supported a previous study that found that daily stomach treatment by 80 mg/kg thymoquinone for 45 days elevated the insulin levels in streptozotocin (STZ)-induced diabetic rats<sup>114</sup>. A clinical study conducted on 60 patients showed that BCSO improved insulin resistance as an adjuvant therapy compared to administering 10 mg Lipitor with 500 mg metformin only per day<sup>115</sup>. Additionally, BCSO resulted in a significant reduction in fasting plasma glucose and an elevation in insulin concentration when compared to

contemporaneous control concentration, with adequate renal and hepatic safety<sup>116</sup>. The effect of BCSO was also investigated on lipid profile and glucose metabolism in patients with diabetes type 2 and data showed that fasting glucose, glycated hemoglobin, triglyceride, and low density lipoprotein-cholesterol (LDL-C) levels were all significantly reduced compared to placebo<sup>117,118</sup>.

#### 4-Pain

There are numerous studies demonstrated the analgesic effect of BCSO as a miracle pain relieving natural product<sup>119-121</sup>. *In-vivo* study confirmed this activity as the oil had a good significant effect against pain generated by injections of 7% acetic acid in dosages of 0.05 ml, 0.1 ml, and 0.2 ml in dependent doses in animal model, respectively<sup>120</sup>. Furthermore another study on an animal model of neuropathic pain demonstrated that BCSO can inhibit neuropathic pain progression and manage hyperalgesia<sup>121</sup>. Mastalgia is the clinical word for a breast ache, which is one of the most annoying things along with many women between the ages of fifteen and forty<sup>122</sup>. It's a deep, painful pain in the breast tissue that some women experience as heaviness, stiffness, irritation, or burning<sup>122</sup>. For women with cyclic Mastalgia, application of BCSO is safe and more effective through administrating of 600 mg twice daily for two months as a topical analgesic compared to topical diclofenac<sup>119</sup>. Another clinical study has been carried out to investigate the pain relieving effect of BCSO on geriatric patients with pain in their knees and results proved its significant efficacy as knee pain analgesic<sup>123</sup>.

#### 5-Skin Disorders

Vitiligo is a skin disorder that results in the loss of skin pigment cells, resulting in white areas<sup>124</sup>. In vitiligo, the skin's melanocytes (pigment-producing cells), mucous membrane, and retina are damaged, resulting in white spots in various locations of the skin<sup>125</sup>. According to estimates, vitiligo affects between 0.1 and 8% of the world's population<sup>126</sup>, while its prevalence in Egypt is around 0.4 and 2%<sup>127</sup>. BCSO was shown to be more effective when combined with others than traditional vitiligo treatments or supplements such as fish oil in reducing size of vitiligo lesions since thymoquinone can mimic the function of acetylcholine and stimulates cholinergic receptors and induces the release of melanin and skin darkening<sup>128</sup>. A cream containing BCSO was effective in sensitive skin areas like the genital region, hands and face when given twice a day for six months to vitiligo patients<sup>129</sup>. Acne vulgaris is another common type of skin disorder caused by chronic inflammatory mechanism<sup>130</sup>. Studies have shown effective response of the acne lesions to BCSO given two times daily for two months<sup>130,131</sup>. The most probable mechanisms for BCSO for management of skin

disorders include the anti-inflammatory effect of BCSO and/or thymoquinone that inhibit *cyclooxygenase* (COX) and 5-lipoxygenase pathways of arachidonate processing and downregulate leukotriene biosynthesis<sup>132,133</sup>. Furthermore, the immunomodulatory and the antimicrobial properties of BCSO that contains  $\alpha$ -pinene against *P. acnes* which play a significant role in acne pathogenesis play a key role in acne treatment<sup>22,134,135</sup>

#### 6- Infertility

Male infertility is a condition that can be caused by a variety of factors, such as abnormal spermatogenesis related to pituitary disorders, testicular cancer, germ cell aplasia, varicocele, and environmental factors, as well as faulty sperm transportation due to birth defects or immunological and neurogenic causes<sup>136</sup>. Infertility affects 8–12% of couples worldwide with male factor infertility (MFI) accounting for 40–50% of the causes<sup>137</sup>, while the exact prevalence of infertility in Egypt is unknown owing to a lack of registration and well-performed studies<sup>138</sup>. A dose of BCSO (1mL/Kg) increased testicular antioxidants and reduced testicular oxidative stress<sup>139</sup>. Smaller doses of BCSO (0.4mL/Kg) boosted sperm concentration, decreased lipid peroxidation and increased glutathione peroxidase, but hadn't any effect on sperm movement and level of testosterone in serum<sup>140</sup>. BCSO acts as a potential protective factor in infertility through stimulation of spermatogenesis, increasing spermatids' quantity and the seminal vesicles weight<sup>141</sup>. Furthermore, co-administration of BCSO with acetamiprid (ACMP) counteracted the negative effects of ACMP-induced reproductive toxicity on reproductive organ mass, semen quality, testosterone, and lower levels of thiobarbituric acid-reactive substances (TBARS) level<sup>141,142</sup>. Alcoholic extract of BCSO particularly at high doses, might raise male rats' reproductive potential, LH, and testosterone levels<sup>143</sup>. After administration of 2.5 mL BCSO twice daily to infertile patients for 60 days, an enhancement in their aberrant sperm morphology, movement and quality without causing any side effects was detected<sup>144</sup>. Additionally, the combination of BCSO (0.5 mL/Kg) with metformin has been improved sperm parameters, blood testosterone levels, mitochondrial membrane potential, and overall body weight in obese individuals with fertility issues<sup>145,146</sup>. BCSO improves sperm quality through several mechanisms including increasing the amount of spermatids and spermatocytes in the cauda epididymis and testicular ducts<sup>147</sup>.

#### 7- Inflammatory disorders

Exaggerated inflammatory cells such as neutrophils, eosinophils, basophils, and mast cells are the main cause for the development of several inflammatory disorders<sup>148</sup>. The activation of mucous glands, vasodilation and increased vascular permeability are all

the physical signs of inflammation, and they are all responsible for common symptoms like itching, sneezing, runny nose, and nasal congestion<sup>149</sup>. *In-vivo* studies testing the anti-inflammatory effect of BCSO in different inflammatory animal models using carrageenan-induced paw oedema, croton oil-induced ear oedema and acetic acid-induced writhing showed that BCSO has a substantial painkiller impact in formalin test and light tail flick tests<sup>150,151</sup>. Allergic rhinitis is one example of the prevalent chronic and allergic condition, particularly among children, and its incidence in populations is rising as a result of industrial work<sup>152</sup>. Clinical studies were performed on allergic rhinitis patients, and clinical findings revealed that BCSO reduced nasal mucosal congestion, itching, runny nose, and sneezing episodes<sup>153-155</sup>. Similar clinical research was performed on 68 volunteers with allergic rhinitis who received BCSO in the form of nasal drops for six weeks, results showed a significant improvement in tolerance of exposure to the active allergen group compared to placebo<sup>156</sup>. Topical use of the BCSO was found to be more successful than systemic treatment in reducing the effect of aggravating variables, which could be owing to BCSO's stronger antihistamine membrane stabilizing effects than the systemic approach probably due to inhibition of Leukotrienes release<sup>157-159</sup>. Another serious common immune-mediated chronic inflammatory skin diseases is psoriasis which is characterized by highly proliferative keratinocytes, dilated blood vessels in the dermis, and a large infiltration of leukocytes<sup>160</sup>. *In-vivo* study showed that topical application of BCSO every day has significantly reduced imiquimod (IMQ)-induced psoriasis-like inflammation and reversed all skin abnormalities<sup>160</sup>. Moreover, a newly developed locally applied combination containing herbal extracts traditionally used in skin problems, such as olive oil, tea tree oil, cocoa butter, and rich source of vitamins with BCSO was found to be a promising remedy for psoriasis due to strong antioxidant properties of BCSO<sup>159,161-163</sup>. Furthermore, the main mechanisms for anti-inflammatory characteristics of BCSO in psoriasis management is inhibiting leukotriene production<sup>164</sup> and histamine production<sup>164</sup>, superoxide scavenger<sup>165</sup>, immunomodulatory effect<sup>22</sup> by increasing T cell-mediated and natural killer cell-mediated immune responses<sup>166</sup>.

Rheumatoid arthritis (RA) is another chronic inflammatory condition that can result in permanent joint damage and severe disability<sup>167</sup>. Patients usually have symmetrical polyarthritis of the tiny joints in their hands and feet, as well as early morning tightness and, on rare occasions, neurological symptoms<sup>168</sup>. The usefulness of BCSO in RA patients was explored and results demonstrated a significant improvement in disease activity<sup>169</sup>. The possible explanation for such activity is

due to inhibition of Eicosanoid production and membrane lipid peroxidation, 5-lipoxygenase and cyclooxygenase by BCSO main components such as TQ<sup>170</sup>. On other side, the antinociceptive actions of BCSO or thymoquinone are mediated by indirect kappa- and mu(1)-opioid receptor activation in the supraspinal nervous system, so supplementing with disease-modifying antirheumatic drugs (DMARD) therapy for rheumatoid arthritis could be considered a cost-effective supplemental therapy<sup>170</sup>.

### 8-Osteoporosis

Osteoporosis is a common illness that results in fragility fractures as a result of a widespread loss of bone mass and microarchitecture<sup>171</sup> with prevalence of 200 million people affected worldwide<sup>172</sup> and 20 millions of Egyptian adults<sup>173</sup>. *In-vivo* study showed BCSO has reversed osteoporosis in ovary-ectomized animals due to its high content of unsaturated fatty acids and antioxidants as well as its anti-inflammatory characteristics<sup>174</sup>. As it was proved that BCSO has a greater degree of unsaturation with linoleic acid and oleic acid<sup>175</sup>. Linoleic acid helps in reducing bone loss by improving calcium absorption in animals<sup>176</sup>. Furthermore, oleic acid raises Ca<sup>+2</sup> levels<sup>177</sup> and promotes nutrient absorption in the body, which helps to maintain bone health and reduce calcium loss<sup>178</sup>. Moreover, BCSO contains useful amounts of calcium, making it a natural origin of calcium supplement for pregnant and nursing women, as well as youngsters and the aged people, which could help to explain the elevated Ca<sup>+2</sup> levels<sup>175</sup>.

### 9-Epilepsy

Epilepsy is a neurological disorder affecting around 70 million people worldwide<sup>179</sup> and involves the occurrence of at least one or more epileptic seizures<sup>180</sup>. Gamma-aminobutyric acid (GABA) is a neurotransmitter that helps to keep the inhibitory tone in the brain and prevents neuronal stimulation<sup>181</sup>. Seizures can occur when the equilibrium between inhibitory and excitatory neurotransmission is disrupted<sup>181</sup>. Functional abnormalities in the central nervous system during epilepsy and seizures have long been known to cause oxidative damage and lipid peroxidation in brain tissues<sup>182</sup>. BCSO was shown to lessen pentylenetetrazol's (PTZ) convulsive and deadly effects in kindled mice and reduce PTZ-induced oxidative toxicity in the tissue of mice brain<sup>183,184</sup>. The combination of BCSO (10 mL/Kg) with sodium valproate (100 mg/kg) and phenytoin sodium (25 mg/kg) as standard medicines in PTZ-induced convulsion has potentiated antioxidant activity and enhanced the level of GABA in the brain, increased neuroprotective effects and prevent episode development<sup>184,185</sup>. Similarly, in another investigation, BCSO in a dose of 10 mL/kg orally for 7 days was shown to

improve malonaldehyde (MDA) level as well as a decrease in glutathione peroxidase and superoxide dismutase levels in the brains of mice who had a PTZ-induced seizure<sup>4</sup>.

## 10- Cancer

The uncontrolled division and proliferation of cells invading healthy tissues is the primary issue triggering the genesis of all cancer types<sup>186</sup>. There were 18 million new cases of cancer diagnosed in 2018, with lung, breast, and prostate cancers accounting for the majority of cases (2,09 million, 2,09 million, and 1,28 million, respectively)<sup>187</sup>. Cancer is triggered by a number of causes, including aberrant DNA methylation<sup>188</sup>, histone deacetylation<sup>189</sup> as well as genetic abnormalities<sup>190</sup>. Different tumor suppressor genes (TSGs) are silenced in cancer as a result of these epigenetic alterations<sup>191</sup>. Another carcinogenic cause is the free radicals build up in the body which produce oxidative stress and inducing carcinogenesis<sup>192</sup>. An earlier investigation revealed that TQ-rich BSCO prevented cancer cells from proliferating and caused them to undergo apoptosis. The interplay between TQ and downregulation of the epigenetic regulators which typically promote cell proliferation and shield cells from apoptosis by blocking the expression of a variety of tumor suppressor genes could be the underlying mechanism<sup>193</sup>. In human adeno- and ductal carcinoma cells including Michigan Cancer Foundation-7 (MCF-7), TQ demonstrated antiproliferative effects by promoting apoptosis through p38 phosphorylation, reactive oxygen species (ROS) production, activating caspases, and Bax while decreasing Bcl-2<sup>4,194</sup>. Moreover, TQ mediated apoptosis in human colon adenocarcinoma HCT116 cells as it inhibited STAT3 pathway<sup>195</sup>. In addition, it significantly inhibited phase-I CYP1A1 enzyme synthesis in hepatic cancer and raised glutathione (GSH) levels in HepG2 cells<sup>196</sup>. Additionally, there is only one *In-vivo* study on TQ in lung cancer, which found that it dramatically boosted tumor apoptosis and blocked pulmonary arterial remodeling in rats given monocrotaline (MCT) treatment<sup>197</sup>. The ability of TQ to induce apoptosis through pro-oxidant effects in tumor xenograft nude mice was demonstrated in a renal cancer *In-vivo* investigation<sup>198</sup>. In a clinical study showed that administration of BCSO (80 mg/kg/day) for seven days after each methotrexate dose was able to reduce methotrexate induced liver toxicity and improved survival in Egyptian children with acute lymphoblastic leukemia as an adjuvant therapy in patients having methotrexate therapy<sup>199</sup>. The proposed mechanisms of anti-cancer activity of BCSO are related to its components such as thymoquinone, carvacrol, *l*-anethole, and 4-terpineol that all have noteworthy donating hydroxyl radical scavenging characteristics for free radicals scavenging properties<sup>54</sup>. Moreover, BCSO

caused a considerable reduction in malonaldehyde (MDA) level in rats treated with carbon tetrachloride<sup>159,200</sup>, and LPS-treated rats<sup>201</sup> as compared to preclinical investigations.

## CONCLUSION

The use of *N. sativa* seed oil and its active ingredient thymoquinone demonstrate varieties of benefits in the management of different diseases such as hypertension, diabetes, obesity, osteoporosis, and other inflammation related diseases linked with oxidative stress. There are different proposed mechanisms of activity for BCSO and main components such as antioxidant, analgesic, modulate glucose and lipid metabolism and serum profiles. Additionally, BCSO can be used in combination therapies with different drugs and supplements for management of many different diseases such as diabetes and cancer. The collective data in the present review is good source for scientists looking for the potential use of medicinal plants such as BCSO and its pure components for future clinical applications on wide screen of diseases since most of its significant consequences have been proved to be positive with minimal side effects. Further clinical and animal studies are required to explore more applications of this magic seed in traditional herbal medicine.

## Funding Acknowledgment

No external funding was received.

## Conflict of interest

The authors declare that they have no conflicts of interest regarding the publication of this paper.

## REFERENCES

1. Thippeswamy N, Naidu KA. Antioxidant potency of cumin varieties—cumin, black cumin and bitter cumin—on antioxidant systems. *Eur. Food Res. Technol.* **2005**;220(5):472-476.
2. Forouzanfar F, Bazzaz BS, Hosseinzadeh H. Black cumin (*Nigella sativa*) and its constituent (thymoquinone): a review on antimicrobial effects. *Iran J. Basic Med. Sci.* **2014**;17(12):929-938. Khazdair MR, Amirabadizadeh A. Therapeutic effects of *Nigella sativa* on asthma: a systematic review of clinical trial. *Physiol. Pharmacol.* **2022**;26(2), 119-126.
3. Ahlina FN, Anggriani L, Aalsabila IA, Jenie RI. Bioactivity of black cumin oil on the senescence of HER-2-overexpressing breast cancer cells. *Malays. Appl. Biol.* **2022**, 51(1), 91-98.
4. Habib MA, Chowdhury AI, Afroze M, Rahman T. Effects of Black Cumin (*Nigella sativa* L.) on patients with cancer and tumor: A systematic Review. *J. Curr. Biomed. Rep.* **2021**;2(1), 38-43.

5. Mahomoodally MF, Aumeeruddy MZ, Legoabe LJ, Montesano D, Zengin G. Nigella sativa L. and Its Active Compound Thymoquinone in the Clinical Management of Diabetes: A Systematic Review. *Int. J. Mol. Sci.* **2022**;23(20):12111. doi: 10.3390/ijms232012111
6. Hadi V, Pahlavani N, Malekhamdi M, Nattagh-Eshativani E, Navashenaq JG, Hadi S, Ferns GA, Ghayour-Mobarhan M, Askari G, Norouzy A. Nigella sativa in controlling Type 2 diabetes, cardiovascular, and rheumatoid arthritis diseases: Molecular aspects. *J. Res. Med. Sci.* **2021**;26. doi: 10.4103/jrms.JRMS\_236\_20
7. Amer Hassan Siddiqui, Nadiya Khan, Shafia Naseer, Arooj Malkera, Shazia Akbar Khan, Ifra Ahsan, Mohammad Israr. Anti-Hypertensive Effect of Nigella Sativa Seeds in Patients with Hypertension. *Pak. J. Med. Health Sci.* **2022**;16(02):86-86.
8. Kamyab R, Namdar H, Torbati M, Ghोजazadeh M, Araj-Khodaei M, Fazljou SMB. Medicinal plants in the treatment of hypertension: A review. *Adv. Pharm. Bull.* **2021**;11(4):601-617.
9. Mousavi SM, Sheikhi A, Varkaneh HK, Zarezadeh M, Rahmani J, Milajerdi A. Effect of Nigella sativa supplementation on obesity indices: A systematic review and meta-analysis of randomized controlled trials. *Complement. Ther. Med.* **2018**;38:48-57.
10. Ermumcu MŞK. Biological activities of black cumin (Nigella sativa) seed oil. In: *Multiple Biological Activities of Unconventional Seed Oils*. Elsevier; **2022**:43-53.
11. Khaldi T, Chekchaki N, Boumendjel M, Taibi F, Abdellaoui M, Messarah M, Boumendjel A. Ameliorating effects of Nigella sativa oil on aggravation of inflammation, oxidative stress and cytotoxicity induced by smokeless tobacco extract in an allergic asthma model in Wistar rats. *Allergol. Immunopathol.* **2018**;46(5):472-481.
12. Elgarf A, Aboromia M, Sabri N, Shaheen S. Amelioration of Endothelial Dysfunction and Inflammation in Type 2 Diabetic Patients after Black Seed Oil Supplementation. *APS.* **2021**;5(2):317-330.
13. Hatipoğlu D, Ozsan M, Dönmez HH, Dönmez N. Hepatoprotective effects of nigella sativa oil against acrylamide-induced liver injury in rats. *Ank. Univ. Vet. Fak.* **2022**:1-22.
14. Erisgin Z, Atasever M, Cetinkaya K, Dizakar SÖA, Omeroglu S, Sahin H. Protective effects of Nigella sativa oil against carboplatin-induced liver damage in rats. *Biomed. Pharmacother.* **2019**;110:742-747.
15. Hammad Shafiq AA, Masud T, Kaleem M. Cardio-protective and anti-cancer therapeutic potential of Nigella sativa. *IJBMS.* **2014**;17(12):967-979.
16. Khan A, Chen H, Tania M, Zhang DZ. Anticancer activities of Nigella sativa (black cumin). *Afr. J. Tradit. Complement. Altern. Med.* **2011**;8(5S). DOI: 10.4314/ajtcam.v8i5S.10
17. Gali-Muhtasib H, Roessner A, Schneider-Stock R. Thymoquinone: A promising anti-cancer drug from natural sources. *Int. J. Biochem. Cell Biol.* **2006**;38(8):1249-1253.
18. Ahmad, A., Husain, A., Mujeeb, M., Khan, S. A., Najmi, A. K., Siddique, N. A., Zoheir A. Damanhoury Anwar, F. A review on therapeutic potential of Nigella sativa: A miracle herb. *Asian Pac. J. Trop. Biomed.* **2013**;3(5):337-352.
19. Hosseinzadeh H, Eskandari M, Ziaee T. Antitussive effect of thymoquinone, a constituent of Nigella sativa seeds, in guinea pigs. *Pharmacologyonline.* **2008**;2, 480-484.
20. Amin B, Hosseinzadeh H. Black cumin (Nigella sativa) and its active constituent, thymoquinone: an overview on the analgesic and anti-inflammatory effects. *Planta medica.* **2016**;82(01/02):8-16.
21. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. *Int. Immunopharmacol.* **2005**;5(13-14):1749-1770.
22. Ali B, Blunden G. Pharmacological and toxicological properties of Nigella sativa. *Phytother. Res.* **2003**;17(4):299-305.
23. Amin B, Taheri MMH, Hosseinzadeh H. Effects of intraperitoneal thymoquinone on chronic neuropathic pain in rats. *Planta medica.* **2014**;80(15):1269-1277.
24. Hosseinzadeh H, Parvardeh S, Asl MN, Sadeghnia HR, Ziaee T. Effect of thymoquinone and Nigella sativa seeds oil on lipid peroxidation level during global cerebral ischemia-reperfusion injury in rat hippocampus. *Phytomedicine.* **2007**;14(9):621-627.
25. Hosseinzadeh H, Taiari S, Nassiri-Asl M. Effect of thymoquinone, a constituent of Nigella sativa L., on ischemia-reperfusion in rat skeletal muscle. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2012**;385(5):503-508.
26. Forouzanfar F, Bazzaz BSF, Hosseinzadeh H. Black cumin (Nigella sativa) and its constituent (thymoquinone): a review on antimicrobial effects. *IJBMS.* **2014**;17(12):929-938.
27. Hosseinzadeh H, Fazly Bazzaz B, Haghi MM. Antibacterial activity of total extracts and essential oil of Nigella sativa L. seeds in mice. *Pharmacologyonline.* **2007**;2:429-435.
28. Chaieb K, Kouidhi B, Jrah H, Mahdouani K, Bakhrouf A. Antibacterial activity of Thymoquinone, an active principle of Nigella sativa and its potency to prevent bacterial biofilm formation. *BMC Complement. Altern. Med.* **2011**;11(1):1-6.

29. Barakat EMF, El Wakeel LM, Hagag RS. Effects of *Nigella sativa* on outcome of hepatitis C in Egypt. *WJG*. **2013**;19(16):2529-2536.
30. Salem ML, Hossain MS. Protective effect of black seed oil from *Nigella sativa* against murine cytomegalovirus infection. *Int. J. Immunopharmacol.* **2000**;22(9):729-740.
31. Mansour MA, Nagi MN, El-Khatib AS, Al-Bekairi AM. Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice: a possible mechanism of action. *Cell biochemistry and function*. **2002**;20(2):143-151.
32. Mohamed AM, Metwally NM, Mahmoud SS. *Sativa* seeds against *Schistosoma mansoni* different stages. *Mem. Inst. Oswaldo Cruz*. **2005**;100:205-211.
33. Baghdadi HB, Al-Mathal EM. Anti-coccidial activity of *Nigella sativa* L. *JFAE*. **2011**;9(2 part 1):10-17.
34. Khan M, Ashfaq M, Zuberi H, Mahmood M, Gilani A. The in vivo antifungal activity of the aqueous extract from *Nigella sativa* seeds. *Phytother. Res.* **2003**;17(2):183-186.
35. Shabana A, El-Menyar A, Asim M, Al-Azzeh H, Al Thani H. Cardiovascular Benefits of Black Cumin (*Nigella sativa*). *Cardiovasc. Toxicol.* **2013**;13(1), 9-21.
36. Razavi BM, Hosseinzadeh H. A review of the effects of *Nigella sativa* L. and its constituent, thymoquinone, in metabolic syndrome. *J. Endocrinol. Investig.* **2014**;37(11):1031-1040.
37. Hosseinzadeh H, Parvardeh S. Anticonvulsant effects of thymoquinone, the major constituent of *Nigella sativa* seeds, in mice. *Phytomedicine*. **2004**;11(1):56-64.
38. Parvardeh S, Nassiri-Asl M, Mansouri M, Hosseinzadeh H. Study on the anticonvulsant activity of thymoquinone, the major constituent of *Nigella sativa* L. seeds, through intracerebroventricular injection. *J. Med. Plant Res.* **2005**;4(14):45-52.
39. Mehri S, Shahi M, Razavi BM, Hassani FV, Hosseinzadeh H. Neuroprotective effect of thymoquinone in acrylamide-induced neurotoxicity in Wistar rats. *IJBMS*. **2014**;17(12):1007-1011.
40. Pourbakhsh H, Taghiabadi E, Abnous K, Hariri AT, Hosseini SM, Hosseinzadeh H. Effect of *Nigella sativa* fixed oil on ethanol toxicity in rats. *IJBMS*. **2014**;17(12):1020-1031.
41. Havakhah, S., Sadeghnia, H. R., Roshan, N. M., Shafiee, S., Hosseinzadeh, H., Mohareri, N., & Rad, A. K. Effect of *Nigella sativa* on ischemia-reperfusion induced rat kidney damage. *IJBMS*. **2014**;17(12):986-992.
42. Mollazadeh H, Hosseinzadeh H. The protective effect of *Nigella sativa* against liver injury: a review. *IJBMS*. **2014**;17(12):958-966.
43. Amini M, Fallah Huseini H, Mohtashami R, Sadeqhi Z, Ghamarchehre MA. Hypolipidemic Effects of *Nigella sativa* L. Seeds Oil in Healthy Volunteers: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *JMPIR*. **2011**;10(40):133-138.
44. Datta AK, Saha A, Bhattacharya A, Mandal A, Paul R, Sengupta S. Black cumin (*Nigella sativa* L.)—a review. *JPDS*. **2012**;4(1):1-43.
45. Datau EA, Wardhana, Surachmanto EE, Pandelaki K, Langi JA, Fias. Efficacy of *Nigella sativa* on serum free testosterone and metabolic disturbances in central obese male. *Acta med. Indones.* **2010**;42(3):130-134.
46. Bilal A, Masud T, Uppal AM. BS5-5 Black seed (*Nigella sativa*) regulates glucose, insulin level and lipid profile in patients with Type 2 diabetes. *J. Diabetes Res.* **2008**;79:19-20.
47. Gupta R. Trends in hypertension epidemiology in India. *J. Hum. Hypertens.* **2004**;18(2):73-78.
48. Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. *Pharmacol. Res.* **2018**;129:95-99.
49. Gumprecht J, Domek M, Lip GYH, Shantsila A. Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management. *J Hum Hypertens.* **2019**;33(12):824-836.
50. Reda A, Ragy H, Saeed K, Alhussaini MA. A semi-systematic review on hypertension and dyslipidemia care in Egypt—highlighting evidence gaps and recommendations for better patient outcomes. *J. Egypt Public Health Assoc.* **2021**;96(1):1-14.
51. Russo C, Olivieri O, Girelli D, Faccini G, Zenari ML, Lombardi S, Corrocher R. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. *J. Hypertens.* **1998**;16(9):1267-1271.
52. Kobayashi A, Ishikawa K, Matsumoto H, Kimura S, Kamiyama Y, Maruyama Y. Synergetic antioxidant and vasodilatory action of carbon monoxide in angiotensin II-induced cardiac hypertrophy. *Hypertension*. **2007**;50(6):1040-1048.
53. J Jaarin K, Foong WD, Yeoh MH, Kamarul ZY, Qodriyah HM, Azman A, Zuhair JS, Juliana AH, Kamisah Y. Mechanisms of the antihypertensive effects of *Nigella sativa* oil in L-NAME-induced hypertensive rats. *Clinics*. **2015**;70:751-757.
54. Niazmand S, Fereidouni E, Mahmoudabady M, Mousavi SM. Endothelium-independent vasorelaxant effects of hydroalcoholic extract from *Nigella sativa* seed in rat aorta: the roles of Ca<sup>2+</sup> and K<sup>+</sup> channels. *Biomed Res. Int.* **2014**;2014.DOI: 10.1155/2014/247054
55. Fallah Huseini, H., Amini, M., Mohtashami, R., Ghamarchehre, M. E., Sadeqhi, Z., Kianbakht, S., Fallah Huseini, A. Blood pressure lowering effect of *Nigella sativa* L. seed oil in healthy volunteers: a randomized, double-blind, placebo-controlled



- clinical trial. *Phytother. Res.* **2013**;27(12), 1849-1853.
56. Khattab MM, Nagi MN. Thymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats. *Phytother. Res.* **2007**;21(5):410-414.
57. El Tahir KE, Ashour MM, Al-Harbi MM. The cardiovascular actions of the volatile oil of the black seed (*Nigella sativa*) in rats: elucidation of the mechanism of action. *Gen. pharmacol.-vasc. sys.* **1993**;24(5):1123-1131.
58. Albakry, Z., Karrar, E., Ahmed, I. A. M., Oz, E., Proestos, C., El Sheikha, A. F., Fatih O., Gangcheng W., Wang, X. Nutritional Composition and Volatile Compounds of Black Cumin (*Nigella sativa* L.) Seed, Fatty Acid Composition and Tocopherols, Polyphenols, and Antioxidant Activity of Its Essential Oil. *Horticulturae.* **2022**;8(7).DOI: 10.3390/horticulturae8070575
59. Miura, K., Stamler, J., Nakagawa, H., Elliott, P., Ueshima, H., Chan, Q., Brown, I., Tzoulaki, I., Saitoh, S., Dyer, A., Daviglius, M., Kesteloot, H., Okayama, A., David Curb, J., Rodriguez, B., Elmer, P., Steffen, L., Robertson, C., Zhao, L. Relationship of dietary linoleic acid to blood pressure: the international study of macro-micronutrients and blood pressure study. *Hypertension.* **2008**;52(2):408-414.
60. Takeuchi, H., Sakurai, C., Noda, R., Sekine, S., Murano, Y., Wanaka, K., Kasai, M., Watanabe, S., Kondo, T. Antihypertensive effect and safety of dietary  $\alpha$ -linolenic acid in subjects with high-normal blood pressure and mild hypertension. *J. Oleo Sci.* **2007**;56(7):347-360.
61. Medina-Remón, A., Zamora-Ros, R., Rotchés-Ribalta, M., Andres-Lacueva, C., Martinez-Gonzalez, M. A., Covas, M. I., D. Corella, J. Salas-Salvadó, E. Gómez-Gracia, V. Ruiz-Gutiérrez, F.J. García de la Corte, M. Fiol, M.A. Pena, G.T. Saez, E. Ros, L. Serra-Majem, X. Pinto, J. Warnberg, R. Estruch, R.M., Lamuela-Raventós, R. M. Total polyphenol excretion and blood pressure in subjects at high cardiovascular risk. *Nutr. Metab. Cardiovasc. Dis.* **2011**;21(5):323-331.
62. Ghosheh OA, Houdi AA, Crooks PA. High performance liquid chromatographic analysis of the pharmacologically active quinones and related compounds in the oil of the black seed (*Nigella sativa* L.). *J. Pharm. Biomed. Anal.* **1999**;19(5), 757-762.
63. Topcagic A, Cavar Zeljkovic S, Karalija E, Galijasevic S, Sofic E. Evaluation of phenolic profile, enzyme inhibitory and antimicrobial activities of *Nigella sativa* L. seed extracts. *BJBMS.* **2017**;17(4):286-294.
64. Carr A, Frei B. The role of natural antioxidants in preserving the biological activity of endothelium-derived nitric oxide. *Free Radical Biology and Medicine.* 2000;28(12):1806-1814.
65. Burits M, Bucar F. Antioxidant activity of *Nigella sativa* essential oil. *Phytother. Res.* **2000**;14(5), 323-328.
66. Sayed HM, El-Latif H, Eid N, Elsayed A, El-Kader E. Potential antihypertensive and antioxidative effects of *Nigella sativa* seeds or biomass and *Syzygium aromaticum* extracts on L-NAME-induced hypertensive rats. *Egypt. Pharm. J.* **2009**;50, 127-146.
67. Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H. Protective role of endothelial nitric oxide synthase. *J. Pathol.* **2003**;199(1):8-17.
68. Ahmad S, Beg ZH. Mitigating role of thymoquinone rich fractions from *Nigella sativa* oil and its constituents, thymoquinone and limonene on lipidemic-oxidative injury in rats. *Springerplus.* **2014**;3(1):1-13.
69. Idris-Khodja N, Schini-Kerth V. Thymoquinone improves aging-related endothelial dysfunction in the rat mesenteric artery. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2012**;385(7):749-758.
70. Sultan MT, Butt MS, Ahmad RS, Pasha I, Ahmad AN, Qayyum MMN. Supplementation of *Nigella sativa* fixed and essential oil mediates potassium bromate induced oxidative stress and multiple organ toxicity. *Pak. J. Pharm. Sci.* **2012**;25(1):175-181.
71. Zaoui A, Cherrah Y, Lacaille-Dubois M, Settaf A, Amarouch H, Hassar M. Diuretic and hypotensive effects of *Nigella sativa* in the spontaneously hypertensive rat. *Therapie.* **2000**;55(3):379-382.
72. Shoaie-Hagh P, Kamelan Kafi F, Najafi S, Zamanzadeh M, Heidari Bakavoli A, Ramezani J, Soltanian S, Asili J, Hosseinzadeh H, Eslami S, Taherzadeh Z. A randomized, double-blind, placebo-controlled, clinical trial to evaluate the benefits of *Nigella sativa* seeds oil in reducing cardiovascular risks in hypertensive patients. *Phytother. Res.* **2021**;35(8):4388-4400.
73. Kopelman PG. Obesity as a medical problem. *Nature.* **2000**;404(6778):635-643.
74. Karlsson EA, Beck MA. The burden of obesity on infectious disease. *EBM.* **2010**;235(12):1412-1424.
75. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. *Diabetes care.* **1994**;17(9):961-969.
76. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. *Ann. Intern. Med.* **1995**;122(7):481-486.
77. de la Maza MP, Estevez A, Bunout D, Klenner C, Oyonarte M, Hirsch S. Ventricular mass in

- hypertensive and normotensive obese subjects. *Int. J. Obes. Relat. Metab. Disord.* **1994**;18(4):193-197.
78. Wolin KY, Carson K, Colditz GA. Obesity and Cancer. *The Oncologist.* 2010;15(6):556-565.
79. Turco G, Bobbio T, Reimão R, Rossini S, Pereira H, Barros Filho A. Quality of life and sleep in obese adolescents. *Arq. Neuro-Psiquiatr.* **2013**;71:78-82.
80. Kopelman P. Sleep apnoea and hypoventilation in obesity. *IJO.* **1992**;16:S37-S42.
81. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. *Metabolism.* **2022**;133:155217. DOI: 10.1016/j.metabol.2022.155217
82. Aboulghate M, Elaghoury A, Elebrashy I, Elkafrawy N, Elshishiney G, Abul-Magd E, Bassiouny E, Toaima D, Elezbawy B, Fasseeh A, Abaza S, Vokó Z. The Burden of Obesity in Egypt. *Public Health Front.* **2021**;9. DOI:10.3389/fpubh.2021.718978
83. Mahdavi R, Namazi N, Alizadeh M, Farajnia S. Effects of Nigella sativa oil with a low-calorie diet on cardiometabolic risk factors in obese women: a randomized controlled clinical trial. *Food & function.* **2015**;6(6):2041-2048.
84. Le PM, Benhaddou-Andaloussi A, Elimadi A, Settaf A, Cherrah Y, Haddad PS. The petroleum ether extract of Nigella sativa exerts lipid-lowering and insulin-sensitizing actions in the rat. *J. Ethnopharmacol.* **2004**;94(2-3):251-259.
85. Safi S, Razmpoosh E, Fallahzadeh H, Mazaheri M, Abdollahi N, Nazari M, Nadjarzadeh A, Salehi-Abargouei A. The effect of Nigella sativa on appetite, anthropometric and body composition indices among overweight and obese women: A crossover, double-blind, placebo-controlled, randomized clinical trial. *Complement. Ther. Med.* **2021**;57:102653. DOI:10.1016/j.ctim.2020.102653
86. Asgary S, Sahebkar A, Goli-Malekabadi N. Ameliorative effects of Nigella sativa on dyslipidemia. *J. Endocrinol. Investig.* **2015**;38(10):1039-1046.
87. Ayed A-L, Talal Z. Long-term effects of Nigella sativa L. oil on some physiological parameters in normal and streptozotocin-induced diabetic rats. *J. Diabetes Mellitus.* 2011;2011.
88. Yin H, Xu L, Porter NA. Free radical lipid peroxidation: mechanisms and analysis. *Chem. Rev.* **2011**;111(10):5944-5972.
89. Namazi N, Mahdavi R, Alizadeh M, Farajnia S. Oxidative stress responses to Nigella sativa oil concurrent with a low-calorie diet in obese women: A randomized, double-blind controlled clinical trial. *Phytother. Res.* **2015**;29(11):1722-1728.
90. Ma Y, Tucker KL, Smith CE, Lee YC, Huang T, Richardson K, Parnell LD, Lai CQ, Young KL, Justice AE, Shao Y, North KE, Ordovás JM. Lipoprotein lipase variants interact with polyunsaturated fatty acids for obesity traits in women: replication in two populations. *NMCD.* **2014**;24(12):1323-1329.
91. Whigham LD, Watras AC, Schoeller DA. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. *AJCN.* **2007**;85(5):1203-1211.
92. Bhatti IU, Rehman FU, Khan MA, Marwat SK. Effect of prophetic medicine Kalonji (Nigella sativa L.) on lipid profile of human beings: an in vivo approach. *World Appl. Sci. J.* **2009**;6(8):1053-1057.
93. Rashidmayvan M, Mohammadshahi M, Seyedian SS, Haghighizadeh MH. The effect of Nigella sativa oil on serum levels of inflammatory markers, liver enzymes, lipid profile, insulin and fasting blood sugar in patients with non-alcoholic fatty liver. *J. Diabetes Metab. Disord.* **2019**;18(2):453-459.
94. Nascimento CM, Ribeiro EB, Oyama LM. Metabolism and secretory function of white adipose tissue: effect of dietary fat. *An. Acad. Bras. Cienc.* **2009**;81:453-466.
95. Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. *Nat. Rev. Nephrol.* **2020**;16(7):377-390.
96. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, Fulcher G, de Galan BE, Harrap S, Hamet P, Heller S, MacMahon S, Marre M, Poulter N, Travert F, Patel A, Neal B, Woodward M. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. *Diabetologia.* **2012**;55(3):636-643.
97. Nathan DM, Group DER. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. *Diabetes Care.* **2014**;37(1):9-16.
98. World Health Organization. Programme on Traditional M. WHO traditional medicine strategy 2002-2005. In. Geneva: World Health Organization; **2002**.
99. Fareed M, Chauhan W, Fatma R, Din I, Afzal M, Ahmed Z. Next-generation sequencing technologies in diabetes research. *Diabetes Epidemiol. Manag.* **2022**;7. DOI: 10.1016/j.deman.2022.100097.
100. Riad M, Elshafei S. An Overview of Diabetes Mellitus in Egypt as a Major Public Health Problem. *NJHS.* **2022**;6(2):80-85.
101. Rchid, H., Chevassus, H., Nmila, R., Guiral, C., Petit, P., Chokaïri, M., & Sauvaire, Y. Nigella sativa seed extracts enhance glucose-induced insulin release from rat-isolated Langerhans islets. *Fundam. Clin. Pharmacol.* **2004**;18(5):525-529.
102. Kanter M, Coskun O, Korkmaz A, Oter S. Effects of Nigella sativa on oxidative stress and  $\beta$ -cell damage

- in streptozotocin-induced diabetic rats. *Anat. Rec.* **2004**;279A(1):685-691.
103. Mansi K. Effects of Oral Administration of Water Extract of *Nigella sativa* on the Hypothalamus Pituitary Adrenal Axis in Experimental Diabetes. *Int. J. Pharmacol.* **2006**;2:104-109.
104. Hmza AJA, Omar E, Adnan A, Osman MT. *Nigella sativa* oil has significant repairing ability of damaged pancreatic tissue occurs in induced type 1 diabetes mellitus. *Glob. J. Pharmacol.* **2013**;7(1):14-19.
105. Fararh KM, Atoji Y, Shimizu Y, Takewaki T. Insulinotropic properties of *Nigella sativa* oil in Streptozotocin plus Nicotinamide diabetic hamster. *Res. Vet. Sci.* **2002**;73(3):279-282.
106. Kanter M, Meral I, Yener Z, Ozbek H, Demir H. Partial Regeneration/Proliferation of the  $\beta$ -Cells in the Islets of Langerhans by *Nigella sativa* L. in Streptozotocin-Induced Diabetic Rats. *TJEM.* **2003**;201(4):213-219.
107. Omar NM, Atia GM. Effect of *Nigella sativa* on pancreatic  $\beta$ -cell damage in streptozotocin-induced diabetic rats: histological and immunohistochemical study. *EJH.* **2012**;35(1):106-116.
108. Fararh K, Atoji Y, Shimizu Y, Shiina T, Nikami H, Takewaki T. Mechanisms of the hypoglycaemic and immunopotentiating effects of *Nigella sativa* L. oil in streptozotocin-induced diabetic hamsters. *Res. Vet. Sci.* **2004**;77(2):123-129.
109. Fararh KM, Atoji Y, Shimizu Y, Shiina T, Nikami H, Takewaki T. Mechanisms of the hypoglycaemic and immunopotentiating effects of *Nigella sativa* L. oil in streptozotocin-induced diabetic hamsters. *Res. Vet. Sci.* **2004**;77(2):123-129.
110. Meddah B, Ducroc R, El Abbes Faouzi M, Eto B, Mahraoui L, Benhaddou-Andaloussi A, Martineau LC, Cherrah Y, Haddad PS. *Nigella sativa* inhibits intestinal glucose absorption and improves glucose tolerance in rats. *J. Ethnopharmacol.* **2009**;121(3):419-424.
111. Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK activation: a therapeutic target for type 2 diabetes? *Diabetes Metab. Syndr. Obes.* **2014**;7:241-253.
112. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. *Nature.* **2001**;414(6865):799-806.
113. Pari L, Sankaranarayanan C. Beneficial effects of thymoquinone on hepatic key enzymes in streptozotocin–nicotinamide induced diabetic rats. *Life Sciences.* **2009**;85(23):830-834.
114. Najmi A, Haque S, Naseeruddin M, Khan R. Effect of *Nigella sativa* oil on various clinical and biochemical parameters of metabolic syndrome. *Int J Diabetes Dev Ctries.* **2008**;16:85-87.
115. Bilal A, Masud T, Uppal AM, Naveed AK. Effects of *Nigella sativa* oil on some blood parameters in type 2 diabetes mellitus patients. *Asian J. Chem.* **2009**;21(7):5373-5381.
116. Heshmati J, Namazi N, Memarzadeh M-R, Taghizadeh M, Kolahdooz F. *Nigella sativa* oil affects glucose metabolism and lipid concentrations in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. *Int. Food Res. J.* **2015**;70:87-93.
117. Abdelrazek H, Kilany OE, Muhammad MA, Tag HM, Abdelazim AM. Black seed thymoquinone improved insulin secretion, hepatic glycogen storage, and oxidative stress in streptozotocin-induced diabetic male Wistar rats. *Oxid. Med. Cell. Longev.* **2018**;2018. DOI: 10.1155/2018/8104165
118. Huseini HF, Kianbakht S, Mirshamsi MH, Zarch AB. Effectiveness of topical *Nigella sativa* seed oil in the treatment of cyclic mastalgia: a randomized, triple-blind, active, and placebo-controlled clinical trial. *Planta Medica.* **2016**;82(04):285-288.
119. Ramadhan UH, Mohammedali MA, Abood HS. Study the analgesic activity of *Nigella sativa* L. volatile oil against pain in mice. *J. Curr. Pharm. Res.* **2011**;5(1):36-38.
120. Talaei SA, Banafshe HR, Moravveji A, Shabani M, Tehrani SS, Abed A. Anti-nociceptive effect of black seed oil on an animal model of chronic constriction injury. *Res. Pharm. Sci.* **2022**;17(4):383-391.
121. Pleasant V. Management of Breast Complaints and High Risk Lesions. *Best Pract. Res. Clin. Obstet. Gynaecol.* **2022**:46-59.
122. Tuna HI, Babadag B, Ozkaraman A, Balci Alparslan G. Investigation of the effect of black cumin oil on pain in osteoarthritis geriatric individuals. *Complement. Ther. Clin. Pract.* **2018**;31:290-294.
123. Grimes PE. White patches and bruised souls: advances in the pathogenesis and treatment of vitiligo. *JAAD.* **2004**;51(1):5-7.
124. Taïeb A. Vitiligo as an inflammatory skin disorder: a therapeutic perspective. *Pigment cell & melanoma research.* **2012**;25(1):9-13.
125. Padmakar S, Murti K, Pandey K, et al. Suicidal ideation associated with vitiligo - A systematic review of prevalence and assessment. *CEGH.* **2022**;17:101140.
126. Khater MH, Abbas RA, Elshobaky OA, Khashaba SA. Prevalence of Hypopigmentary Disorders in Primary School Children in Zagazig City, Sharkia Governorate, Egypt. *J. Cosmet. Dermatol.* **2022**;21(3):1208-1215.
127. Ghorbanibirgani A, Khalili A, Rokhafrooz D. Comparing *Nigella sativa* oil and fish oil in treatment of vitiligo. *Iran. Red. Crescent. Med. J.* **2014**;16(6): e4515.

128. Ali SA, Meitei KV. Nigella sativa seed extract and its bioactive compound thymoquinone: the new melanogens causing hyperpigmentation in the wall lizard melanophores. *JPP*. **2011**;63(5):741-746.
129. Al-Harchan NA-AH. Treatment of Acne Vulgaris with Nigella sativa oil lotion. *Iraqi Acad Sci J*. **2010**;9(2):140-144.
130. Soleymani, S., Zargaran, A., Farzaei, M. H., Iranpanah, A., Heydarpour, F., Najafi, F., & Rahimi, R. The effect of a hydrogel made by Nigella sativa L. on acne vulgaris: A randomized double-blind clinical trial. *Phytother. Res*. **2020**;34(11), 3052-3062.
131. Kohandel Z, Farkhondeh T, Aschner M, Samarghandian S. Anti-inflammatory effects of thymoquinone and its protective effects against several diseases. *Biomed. Pharmacother*. **2021**;138:111492.DOI: 10.1016/j.biopha.2021.111492
132. El Gazzar M, El Mezayen R, Marecki JC, Nicolls MR, Canastar A, Dreskin SC. Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. *Int. Immunopharmacol*. **2006**;6(7):1135-1142.
133. Farrar MD, Ingham E. Acne: inflammation. *Clin. Dermatol*. **2004**;22(5):380-384.
134. El-Tahir KE-DH, Bakeet DM. The black seed Nigella sativa Linnaeus-A mine for multi cures: a plea for urgent clinical evaluation of its volatile oil. *JTUMED*. **2006**;1(1):1-19.
135. Iammarrone E, Balet R, Lower AM, Gillott C, Grudzinskas JG. Male infertility. *Best Pract. Res. Clin. Obstet. Gynaecol*. **2003**;17(2):211-229.
136. M. Hofny E, Abdel Hafez H, Abdel Aalb M, Abdel Tawab F. Effect of male infertility on quality of life. *J. Curr. Med. Res. Pract*. **2021**;6(3):311-317.
137. Ombelet W, Cooke I, Dyer S, Serour G, Devroey P. Infertility and the provision of infertility medical services in developing countries. *Hum. Reprod. Update*. **2008**;14(6):605-621.
138. Mosbah R, Yousef MI, Mantovani A. Nicotine-induced reproductive toxicity, oxidative damage, histological changes and haematotoxicity in male rats: the protective effects of green tea extract. *Exp. Toxicol. Pathol*. **2015**;67(3):253-259.
139. Mansour SW, Sangi S, Harsha S, Khaleel MA, Ibrahim A. Sensibility of male rats fertility against olive oil, Nigella sativa oil and pomegranate extract. *Asian Pac. J. Trop. Biomed*. **2013**;3(7):563-568.
140. Mosbah R, Djerrou Z, Mantovani A. Protective effect of Nigella sativa oil against acetamiprid induced reproductive toxicity in male rats. *Drug Chem. Toxicol*. **2018**;41(2):206-212.
141. Mohamadin AM, Sheikh B, Abd El-Aal AA, Elberry AA, Al-Abbasi FA. Protective effects of Nigella sativa oil on propoxur-induced toxicity and oxidative stress in rat brain regions. *Pestic. Biochem. Phys*. **2010**;98(1):128-134.
142. Parandin R, Yousofvand N, Ghorbani R. The enhancing effects of alcoholic extract of Nigella sativa seed on fertility potential, plasma gonadotropins and testosterone in male rats. *Iran. J. Reprod. Med*. **2012**;10(4):355-362.
143. Kolahdooz M, Nasri S, Modarres SZ, Kianbakht S, Huseini HF. Effects of Nigella sativa L. seed oil on abnormal semen quality in infertile men: a randomized, double-blind, placebo-controlled clinical trial. *Phytomedicine*. **2014**;21(6):901-905.
144. Leisegang K, Almaghrawi W, Henkel R. The effect of Nigella sativa oil and metformin on male seminal parameters and testosterone in Wistar rats exposed to an obesogenic diet. *Biomed. Pharmacother*. **2021**;133:111085.DOI: 10.1016/j.biopha.2020.111085
145. Bashandy AS. Effect of fixed oil of Nigella sativa on male fertility in normal and hyperlipidemic rats. *Int. J. Pharmacol*. **2007**;3(1):27-33.
146. Mohammad MA, Mohamad M, Dradka H. Effects of black seeds (Nigella sativa) on spermatogenesis and fertility of male albino rats. *Res. J. Med. Sci*. **2009**;4(2):386-390.
147. Fransson M, Benson M, Erjefält JS, Jansson L, Uddman R, Björnsson S, Cardell LO, Adner M. Expression of Toll-like Receptor 9 in nose, peripheral blood and bone marrow during symptomatic allergic rhinitis. *Respir. Res*. **2007**;8(1):17:1-13.
148. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, Simmons AL, Wingertzahn MA, Boyle JM. Burden of allergic rhinitis: Results from the Pediatric Allergies in America survey. *J. Allergy Clin. Immunol*. **2009**;124(3, Supplement 1):S43-S70.
149. Hajhashemi V, Ghannadi A, Jafarabadi H. Black cumin seed essential oil, as a potent analgesic and antiinflammatory drug. *Phytother. Res*. **2004**;18(3): 195-199.
150. Mutabagani A, El-Mahdy SA. A study of the anti-inflammatory activity of Nigella sativa L. and thymoquinone in rats. *SPJ*. **1997**;5:110-113.
151. Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the common cold – high cost to society. *Allergy*. **2010**;65(6):776-783.
152. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. *Lancet*. **2011**;378(9809), 2112-2122.
153. Nikakhlagh S, Rahim F, Aryani FHN, Syahpoush A, Brougerdnya MG, Saki N. Herbal treatment of allergic rhinitis: the use of Nigella sativa. *Am. J. Otolaryngol*. **2011**;32(5):402-407.

154. Al-Ghamdi MS. The anti-inflammatory, analgesic and antipyretic activity of *Nigella sativa*. *J. Ethnopharmacol.* **2001**;76(1):45-48.
155. Mohamed Alsamara A, Abdulsatar M, Hamed Ahmed Alobaidi A. Evaluation of topical black seed oil in the treatment of allergic rhinitis. *Curr. Med. Chem.-Anti-Inflamm. and Anti-Aller. Agents.* **2014**;13(1):75-82.
156. Houghton PJ, Zarka R, de las Heras B, Hoult JRS. Fixed Oil of *Nigella sativa* and Derived Thymoquinone Inhibit Eicosanoid Generation in Leukocytes and Membrane Lipid Peroxidation. *Planta Med.* **1995**;61(01):33-36.
157. Chakravarty N. Inhibition of histamine release from mast cells by nigellone. *Ann. Allergy.* **1993**;70(3):237-242.
158. Kanter M, Coskun O, Uysal H. The antioxidative and antihistaminic effect of *Nigella sativa* and its major constituent, thymoquinone on ethanol-induced gastric mucosal damage. *Arch. Toxicol.* **2006**;80(4):217-224.
159. Okasha EF, Bayomy NA, Abdelaziz EZ. Effect of Topical Application of Black Seed Oil on Imiquimod-Induced Psoriasis-like Lesions in the Thin Skin of Adult Male Albino Rats. *Anat. Resc.* **2018**;301(1):166-174.
160. Sultan MT, Butt MS, Karim R, Ahmed W, Kaka U, Ahmad S, Dewanjee S, Jaafar HZ, Zia-Ul-Haq M.. *Nigella sativa* fixed and essential oil modulates glutathione redox enzymes in potassium bromate induced oxidative stress. *BMC Complement. Altern. Med.* **2015**;15(1):330:1-8.
161. Young CN, Koepke JI, Terlecky LJ, Borkin MS, Boyd SL, Terlecky SR. Reactive oxygen species in tumor necrosis factor- $\alpha$ -activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. *JID.* **2008**;128(11):2606-2614.
162. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, Tschachler E, Wagner EF. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. *Nature.* **2005**;437(7057):369-375.
163. Ikhsan M, Hiedayati N, Maeyama K, Nurwidya F. *Nigella sativa* as an anti-inflammatory agent in asthma. *BMC Res. Notes.* **2018**;11(1):1-5.
164. Demir E, Taysi S, Ulusal H, Kaplan DS, Cinar K, Tarakcioglu M. *Nigella sativa* oil and thymoquinone reduce oxidative stress in the brain tissue of rats exposed to total head irradiation. *Int. J. Radiat. Biol.* **2020**;96(2):228-235.
165. El-Shanshory, M., Hablas, N. M., Aboonq, M. S., Fakhreldin, A. R., Attia, M., Arafa, W., Mariah, R. A., Hussam Baghdadi, Mongi Ayat, Mohammed Zolaly, Nabo, M. M. H., Almaramhy, H. H., El-Sawy, S. A., Zidan, M., Momen Elshazley, Rami Alharbi, Sayed Moustafa, Naga, M. A., El-Sayed, S. M. *Nigella sativa* improves anemia, enhances immunity and relieves iron overload-induced oxidative stress as a novel promising treatment in children having beta-thalassemia major. *J. Herb. Med.* **2019**;16:100245. DOI: 10.1016/j.hermed.2018.11.001
166. Ostrowska M, Maśliński W, Prochorec-Sobieszek M, Niciecki M, Sudoł-Szopińska I. Cartilage and bone damage in rheumatoid arthritis. *Rheumatol.* **2018**;56(2):111-120.
167. Ngian GS. Rheumatoid arthritis. *Aust. Fam. Physician.* **2010**;39(9):626-628.
168. Gheita TA, Kenawy SA. Effectiveness of *Nigella sativa* Oil in the Management of Rheumatoid Arthritis Patients: A Placebo Controlled Study. *Phytother. Res.* **2012**;26(8):1246-1248.
169. Gali-Muhtasib H, El-Najjar N, Schneider-Stock R. The medicinal potential of black seed (*Nigella sativa*) and its components. *Adv. Phytomedicine.* **2006**;2, 133-153.
170. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. *Lancet.* **2011**;377(9773), 1276-1287.
171. De Martinis M, Sirufo MM, Polsinelli M, Placidi G, Di Silvestre D, Ginaldi L. Gender Differences in Osteoporosis: A Single-Center Observational Study. *WJMH.* **2021**;39(4):750-759.
172. El Miedany, Y., Abu-Zaid, M., El Gaafary, M., El Naby, M., Fathi N., Saber H., Hassan, W., Eissa M., Mohannad N., Khaled H., Mortada M., Nasef S., Galal, S., Ghaleb R., Tabra S., Mohamed S., Medhat B., Aly H., Elolemy G., Fouad N., Ganab S., Adel Y., Ibrahim M., Farouk O. and Gadallah N. Egyptian consensus on treat-to-target approach for osteoporosis: a clinical practice guideline from the Egyptian Academy of bone health and metabolic bone diseases. *ERAR.* **2021**;48(1):5:1-16.
173. Seif AA. *Nigella Sativa* reverses osteoporosis in ovariectomized rats. *BMC Complement. Altern. Med.* **2014**;14(1):22:1-8.
174. Ali MA, Sayeed MA, Alam MS, Yeasmin MS, Khan AM, Muhamad II. Characteristics of oils and nutrient contents of *Nigella sativa* Linn. and *Trigonella foenum-graecum* seeds. *BCSE.* **2012**;26(1). DOI: 10.4314/bcse.v26i1.6
175. Kelly O, Cusack S, Jewell C, Cashman KD. The effect of polyunsaturated fatty acids, including conjugated linoleic acid, on calcium absorption and bone metabolism and composition in young growing rats. *BJN.* **2003**;90(4):743-750.
176. Carrillo C, Cavia Md, Alonso-Torre SR. Oleic acid inhibits store-operated calcium entry in human colorectal adenocarcinoma cells. *Eur. J. Nutr.* **2012**;51(6):677-684.

177. Shuid AN, Ping LL, Muhammad N, Mohamed N, Soelaiman IN. The effects of *Labisia pumila* var. *alata* on bone markers and bone calcium in a rat model of post-menopausal osteoporosis. *J. Ethnopharmacol.* **2011**;133(2):538-542.
178. Abdel-Whahed wY, Shaheen HA, Thabet SH, Hassan SK. Epidemiology of Epilepsy in Fayoum Governorate, Egypt: A Community-based Study. *EFMJ.* **2022**;6(1):19-33.
179. Schmidt D, Löscher W. Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms. *Epilepsia.* **2005**;46(6):858-877.
180. Treiman DM. GABAergic Mechanisms in Epilepsy. *Epilepsia.* **2001**;42(s3):8-12.
181. Parfenova H, Leffler CW, Basuroy S, Fedinec AL. Antioxidant roles of heme oxygenase, carbon monoxide and bilirubin in cerebral circulation during epileptic seizures. *FASEB J.* **2012**;26(S1):685.624-685.624.
182. Ilhan A, Gurel A, Armutcu F, Kamisli S, Iraz M. Antiepileptogenic and antioxidant effects of *Nigella sativa* oil against pentylenetetrazol-induced kindling in mice. *Neuropharmacol.* **2005**;49(4):456-464.
183. El Nabtity S, Shaban A, salah m. Anticonvulsant and GABAergic Activity of *Nigella sativa* oil in Mice. *Zagazig Vet. J.* **2019**;0(0):11-20.
184. Aboul Ezz HS, Khadrawy YA, Noor NA. The Neuroprotective Effect of Curcumin and *Nigella sativa* Oil Against Oxidative Stress in the Pilocarpine Model of Epilepsy: A Comparison with Valproate. *Neurochem. Res.* **2011**;36(11):2195-2204.
185. Lega IC, Lipscombe LL. Review: Diabetes, Obesity, and Cancer—Pathophysiology and Clinical Implications. *Endocr. Rev.* **2019**;41(1):33-52.
186. Mattiuzzi C, Lippi G. Current Cancer Epidemiology. *J. Epidemiol. Glob. Health.* **2019**;9(4):217-222.
187. Usui G, Matsusaka K, Mano Y, Urabe M, Funata S, Fukayama M, Ushiku T, Kaneda A. DNA methylation and genetic aberrations in gastric cancer. *Digestion.* **2021**;102(1):25-32.
188. Zhou M, Yuan M, Zhang M, Lei C, Aras O, Zhang X, An F. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. *Eur. J. Med. Chem.* **2021**;226:113825. DOI: 10.1016/j.ejmech.2021.113825 Sugiura, M., Sato, H., Kanesaka, M., Imamura, Y., Sakamoto, S., Ichikawa, T., Kaneda, A. Epigenetic modifications in prostate cancer. *Int. J. Urol.* **2021**;28(2):140-149.
189. Baylin SB, Jones PA. Epigenetic Determinants of Cancer. *Cold Spring Harbor perspectives in biology.* **2016**;8(9):a019505.
190. Silva RF, Pogačnik L. Polyphenols from food and natural products: Neuroprotection and safety. *Antioxidants.* **2020**;9(1):61. DOI: 10.3390/antiox9010061
191. Alsanosi S, Sheikh RA, Sonbul S, Altayb HN, Batubara AS, Hosawi S, Al-Sakkaf K, Abdullah O, Omran Z, Alhosin M. The Potential Role of *Nigella sativa* Seed Oil as Epigenetic Therapy of Cancer. *Molecules.* **2022**;27(9):2779. DOI: 10.3390/molecules27092779
192. Khurshid Y, Syed B, Simjee SU, Beg O, Ahmed A. Antiproliferative and apoptotic effects of proteins from black seeds (*Nigella sativa*) on human breast MCF-7 cancer cell line. *BMC complement. med. ther.* **2020**;20(1):1-11.
193. Kundu J, Choi BY, Jeong C-H, Kundu JK, Chun K-S. Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2-and Src-mediated phosphorylation of EGF receptor tyrosine kinase. *Oncol. Rep.* **2014**;32(2):821-828.
194. Ashour AE, Abd-Allah AR, Korashy HM, Attia SM, Alzahrani AZ, Saquib Q, Bakheet SA, Abdel-Hamied HE, Jamal S, Rishi AK. Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis. *Mol. Cell. Biochem.* **2014**;389(1), 85-98.
195. Zhu N, Zhao X, Xiang Y, Ye S, Huang J, Hu W, Lv L, Zeng C. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats. *Int. J. Cardiol.* **2016**;221, 587-596.
196. Chae IG, Song N-Y, Kim D-H, Lee M-Y, Park J-M, Chun K-S. Thymoquinone induces apoptosis of human renal carcinoma Caki-1 cells by inhibiting JAK2/STAT3 through pro-oxidant effect. *FCT.* **2020**;139:111253. DOI: 10.1016/j.fct.2020.111253
197. A Hagag A, M AbdElaal A, S Elfaragy M, M Hassan S, A Elzamarany E. Therapeutic value of black seed oil in methotrexate hepatotoxicity in Egyptian children with acute lymphoblastic leukemia. *Curr. Drug Targets Infect. Disord.* **2015**;15(1):64-71.
198. Al-Seeni MN, El Rabey HA, Zamzami MA, Alnefayee AM. The hepatoprotective activity of olive oil and *Nigella sativa* oil against CCl4 induced hepatotoxicity in male rats. *BMC Complement. Altern. Med.* **2016**;16(1):438-1-14.
199. Beheshti F, Norouzi F, Abareishi A, Khazaei M, Alikhani V, Moussavi S, Biglari G, Soukhtanloo M, Hosseini M. *Nigella sativa* prevented liver and renal tissue damage in lipopolysaccharide-treated rats. *SJKDT.* **2018**;29(3):554-566.